Drug Profile
GLPG 1837
Alternative Names: ABBV 974; GLPG1837Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
- Developer Galapagos NV
- Class
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 29 Sep 2021 Discontinued - Phase-I for Cystic fibrosis (In volunteers) in Belgium (PO)
- 29 Sep 2021 Discontinued - Phase-II for Cystic fibrosis in Australia, Czech Republic, Germany, Ireland, United Kingdom (PO)
- 29 Sep 2021 Discontinued - Phase-II for Cystic fibrosis in Belgium, Netherlands (PO)